Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/08/26	USD 0.1860	+1.31%	2,618,804
07/08/26	USD 0.1836	+2.86%	8,232,643
06/08/26	USD 0.1785	+8.84%	5,250,259
05/08/26	USD 0.1640	+1.86%	1,802,190
04/08/26	USD 0.1610	+0.94%	1,216,042

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1860USD

Average target price

1.000USD

Spread / Average Target

+437.63%

Consensus

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 05:59:59 11/08/26 am AEST			5-day change	1st Jan Change
0.1860 ^USD	+1.31%		+16.61%	-18.69%

07/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI

Market Cap	314M 272M 254M 232M 438M 29.95B 444M 2.98B 1.17B 14.98B 1.18B 1.15B 49.9B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	410M 355M 332M 303M 571M 39.11B 580M 3.89B 1.53B 19.57B 1.54B 1.51B 65.16B	EV / Sales 2026 *	-	EV / Sales 2027 *	11.3x
Free-Float	95.3%	Yield 2026 *	-	Yield 2027 *	-

07/08	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
01/11/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
19/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI

07/08	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
09/07	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
03/07	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
16/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
01/05	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR

Northwest Biotherapeutics, Inc. Stock

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Chart: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Northwest Biotherapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 day	+1.31%
1 week	+16.61%
Current month	+13.41%
1 month	+4.49%
3 months	-20.17%
6 months	-25.75%
Current year	-18.69%

1 week	0.16	0.21
1 month	0.14	0.21
Current year	0.14	0.34
1 year	0.14	0.37
3 years	0.14	1.09
5 years	0.14	2.05
10 years	0.14	2.51

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/8/24	Alton Boynton	Don	Founder	1,000,000	0.0826%
9/8/24	Marnix Bosch	Don	Chief Technology Officer	3,000,000	0.2478%
8/8/24	Alton Boynton	Don	Founder	1,000,000	0.0826%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	+1.31%	+16.61%	-25.00%	-63.81%	314M
WUXI APPTEC CO., LTD.	+4.21%	+25.56%	+77.96%	+104.49%	70.85B
ARGENX SE	+0.50%	+6.20%	+34.94%	+67.83%	55.41B
INSMED INCORPORATED	+2.78%	+36.87%	+23.00%	+493.09%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	+1.60%	+18.87%	+57.08%	+5.18%	24.12B
BIONTECH SE	-0.93%	+0.60%	-16.89%	-12.00%	23.31B
GENMAB A/S	-0.35%	+7.91%	+44.14%	-22.61%	18.37B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.57%	+10.84%	+31.14%	+628.97%	16.1B
PHARMAESSENTIA CORPORATION	+7.26%	+14.16%	+221.03%	+393.89%	16.99B
EXELIXIS, INC.	-2.05%	-3.81%	+40.40%	+150.40%	13.12B
Average	+1.13%	+10.69%	+48.78%	+174.54%	26.8B
Weighted average by Cap.	+1.71%	+11.60%	+54.88%	+163.70%

	2026 *	2027 *
Net sales	-	38.93M 33.71M 31.5M 28.79M 54.26M 3.71B 55.11M 369M 145M 1.86B 146M 143M 6.19B
Net income	-	-
Net Debt	96.08M 83.18M 77.74M 71.05M 134M 9.16B 136M 912M 358M 4.58B 361M 353M 15.27B	125M 108M 101M 92.4M 174M 11.92B 177M 1.19B 465M 5.96B 469M 459M 19.85B